Concord Biotech Ltd (CONCORDBIO) — Announcement | 17 September 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Concord Biotech announces investor meeting schedule with JP Morgan Healthcare
💡 Investor Takeaway
Investors can attend scheduled meetings to discuss the company's publicly available information.

Concord Biotech announced its schedule for upcoming analyst and institutional investor meetings in Ahmedabad on September 23, 2026, organized by JP Morgan Healthcare. The sessions will discuss publicly available information without any unpublished price sensitive material, with a note that timings may change due to host or company exigencies. The filing confirms regulatory compliance with SEBI LODR requirements for investor engagement.

📄 View Original Announcement (PDF)

About Concord Biotech Ltd (CONCORDBIO)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹15,212.77 Cr P/E: 55.7 ROE: 13.5% ROCE: 18.1% Div Yield: 0.52%

View full CONCORDBIO stock details →

📡 Get AI alerts when CONCORDBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CONCORDBIO — Free

📊 More CONCORDBIO filings

See all CONCORDBIO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CONCORDBIO files new disclosures

Track CONCORDBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CONCORDBIO — Free

Free account · 2 AI queries/day